title: Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
abstract: A 63-year-old man with chronic lymphocytic leukaemia developed pyoderma gangrenosum following minor trauma to the leg. He required intensive inpatient management with a multitude of treatments including larval therapy, surgical debridement, ciclosporin, methotrexate, thalidomide, pulsed intravenous methylprednisolone and high-dose intravenous immunoglobulin, clofazamine and high dose oral corticosteroids, none of which were helpful. Treatment complications included steroid-induced diabetes, Cushing's syndrome and perforated peptic ulcer. The pyoderma remained refractory to treatment and continued to extend until he received intravenous infliximab 5 mg/kg at weeks 0, 2 and 6.
authors.affiliation: Department of Dermatology, Royal Free Hospital, London, UK. vjswale@doctors.org.uk
authors.forename: V J
authors.initials: VJ
authors.lastname: Swale
authors.forename: M
authors.initials: M
authors.lastname: Saha
authors.forename: N
authors.initials: N
authors.lastname: Kapur
authors.forename: A V
authors.initials: AV
authors.lastname: Hoffbrand
authors.forename: M H A
authors.initials: MH
authors.lastname: Rustin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab